¿A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)¿

  • Markowitz, Avi (PI)

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date7/30/13 → 12/31/16

    Funding

    • Bayer HealthCare Pharmaceuticals: $21,546.00